Ubl’s Successor At AdvaMed Will Struggle To Maintain User Fee Stability
This article was originally published in The Gray Sheet
Executive Summary
AdvaMed Exec VP-Federal Government Relations Steve Ubl will be absent from the negotiating table July 15 when FDA meets with industry reps to discuss counterproposals to an 18% hike in 2005 user fee rates